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The individual, familial and societal consequences
of diabetes mark it out as a condition of major im-
portance to us all. The rising prevalence rates of
Type II diabetes and the numbers of younger pa-
tients who are diagnosed with the condition may
be functionally related to the impoverished life-
style of the modern era, but the problem of coping
with diabetes is not alleviated by simply recogniz-
ing this association—patients need effective treat-
ment. In the treatment and management of diabe-
tes, as with interventions in other diseases and
conditions, the measurement of outcomes pro-
vides crucial intelligence for the patient, the health
care professional and the researcher alike. The
past 25 years have seen the growing acceptance of
measures of health-related quality of life (HrQoL).
In the context of diabetes, such measures can re-
veal much of the burden of the condition, includ-
ing aspects of psychological functioning. There
seems little doubt too, that such measures are gen-
erally capable of reflecting real differences be-
tween patients with different levels of comorbid-
ity. However, Luscombe’s comprehensive review
of HrQoL instruments (pp S-15–S-28) notes that
much of the research in this area has been cross-
sectional in nature and as a consequence little is
known about responsiveness of many measures
to clinical change and treatment effects. This is
an important consideration in the investigation of
HrQoL when adopted as an endpoint in clinical
studies. One such cross-sectional study conducted
amongst UK diabetics is reported by Holmes et al.
(pp S-47–S-51). Using results derived from a postal
survey in which a standardized measure of health-
related quality of life was fielded, they demon-
strate the diabetic burden by referring to age-stan-
dardized reference levels of HrQoL reported by
the general public.
The economic burden of diabetes is likely to
impact on us all, either directly or indirectly. The
increased use of guidelines is sometimes portrayed
as a means of ensuring that best clinical practice is
delivered, but in the absence of appropriate eco-
nomic evidence to complement the clinical portfo-
lio adherence to guidelines may unwittingly lead
to financial disadvantage. In reporting on the as-
sociation between total expenditure and adher-
ence to practice guidelines Ozminkowski (pp S-29–
S-38) suggests that in the short-run at least, higher
than necessary expenditures are a consequence.
Studies that monitor the health outcomes for pa-
tients over significant periods would be needed to
firm up such an inference. Although not always
designed with the policy analyst in mind, it is nev-
ertheless the case that any study that investigates
both the costs and benefits of interventions is now
capable of being interpreted as part of a much
wider agenda. The closer scrutiny afforded by reg-
ulatory agencies means that the audience for eco-
nomic studies is becoming more demanding in its
needs. The actors too, are becoming more adept in
rehearsing their evidence. Oliver and Pritchard (pp
S-7–S-14) note the dominance of cost-consequence
studies in the literature and the relative paucity of
studies that carry sustainable information of pol-
icy relevance. Reliance on modeling can only be
considered a short-term expedient although it is in
this area that practice appears to conform most
closely to the methods advocated by the Washing-
ton Panel on Cost-Effectiveness in Medicine. An
example of one such modeling study is reported
here, in which Persson et al. (pp S-39–S-46) exam-
ine the cost-effectiveness of treating leg ulcers
These papers selected for this special issue of
Value in Health bear on many of the central
themes that resonate with health care decision-
makers and patients alike.
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